Oncology

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Discussions at this February IVBM evening covered advances in biomarker testing in lung cancer to the real-life challenges of maintaining diversity in clinical trials.

The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, says Estelamari Rodriguez, MD, MPH.

Panelists at a Boston Regional Institute for Value-Based Medicine event examined trial diversity, integrated dispensing, and evolving oncology pathways.

Less than half of US adults aged 45 to 49 years were up to date on colorectal cancer (CRC) screening in 2023, suggesting that age group–specific interventions may improve CRC screening in the US.

Higher social vulnerability was associated with lower dietary fiber intake and a hostile gut microbiome in patients with melanoma or sarcoma receiving immune checkpoint blockade.

Male patients and those from minoritized racial and ethnic groups face longer times to treatment, especially in urban areas.

Racial gaps in curative treatment for early-stage NSCLC persist among Medicare beneficiaries, with Black patients less likely to receive surgery.

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.

Smarter therapies, evolving frailty tools, and more inclusive trials are finally extending myeloma's survival gains to older adults.

Thyme Care bets on ePRO-driven toxicity monitoring to cut Medicare oncology adverse events, infections and ED visits—making value-based care finally work.

Galleri trial data show liquid biopsy multicancer early detection tests may cut stage IV diagnoses, despite the missed primary end point.

The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.

A study of 1.5 million patients suggests that ACA Medicaid expansion reduces breast cancer deaths, especially advanced cases—yet racial and income gaps persist.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

Enfortumab vedotin plus pembrolizumab boosts survival and pCR in muscle-invasive bladder cancer, according to EV-304 trial data.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Emerging CRC diagnostic tools along with better public awareness could help reverse rising deaths in younger adults, says Jordan Karlitz, MD.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.